APR-246

3:33
Targeting BCL-2 in older AML: novel venetoclax combinations
Andrew Wei
3:24
Data for APR-246 and azacitidine in patients with mTP53 MDS and AML
David Sallman
1:56
Promising approaches and clinical trials in MDS
David Steensma
1:06
Is there hope for treating TP53-mutated MDS?
Mark Levis
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals